智通财经APP获悉，再鼎医药(09688)尾盘涨超5%，截至发稿，涨4.89%，报16.1港元，成交额2.47亿港元。
消息面上，再鼎医药近期宣布，美国FDA已授予具有同类首创潜力的靶向Delta样配体3(DLL3)的抗体药物偶联物(ADC)zocilurtatug pelitecan(zoci，前称ZL-1310)快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。此前，2025年5月，Zoci已获FDA快速通道资格，用于广泛期小细胞肺癌(ES-SCLC)治疗。
值得注意的是，再鼎医药合作伙伴argenx近日宣布，美国FDA已批准VYVGART(艾加莫德静脉输注剂型)和VYVGART Hytrulo(艾加莫德皮下注射剂型)的适应证拓展，用于治疗所有成人gMG患者。据悉，2021年1月，再鼎医药引进了艾加莫德的大中华区权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.